TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Mar 23, 2021 18:34 JST
Source:
Eisai
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan
TOKYO, Mar 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma. This marks the first approval for LENVIMA for unresectable thymic carcinoma in Japan.
The approval was based on the results of an open-label, single-arm, multicenter, investigator-initiated clinical phase II study (REMORA study) conducted in 8 centers across Japan including the National Cancer Center Hospital, evaluating LENVIMA as a single agent in 42 patients with thymic carcinoma previously treated with at least one platinum-based regimen.
LENVIMA met the study's primary endpoint of objective response rate (ORR) as assessed by independent imaging review, demonstrating an ORR of 38.1% (90% confidence interval (CI): 25.6-52.0). The lower value of the CI exceeded the pre-specified statistical criteria with a threshold ORR of 10%. The most common three treatment-related adverse events were hypertension (88.1%), proteinuria (71.4%), and palmar-plantar erythrodysesthesia syndrome (69.0%), which is consistent with the safety profile observed in the previously approved indications.
Thymic carcinoma is an extremely rare disease with low prevalence. It is estimated that there are about 140 patients in Japan. For unresectable thymic carcinoma, platinum-based first-line therapy is recommended. However, since the standard treatment has not yet been established for second-line or later therapy, this is an area of high unmet medical need. In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.
Eisai and MSD have been collaborating through the provision of information on LENVIMA in Japan since October 2018, and will work together to expedite the maximization of LENVIMA's contribution to patients with cancer.
Source: Eisai
Sectors: BioTech
Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai and National Cancer Center Commence Joint Research and Development Project
May 14 2021 16:48 JST
Eisai's Statement of Commitment for Carbon Neutrality by 2040
May 11 2021 09:00 JST
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications
May 07 2021 10:08 JST
RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan
April 28 2021 11:33 JST
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan
April 23 2021 13:55 JST
Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies
April 23 2021 12:02 JST
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease
April 23 2021 08:07 JST
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease
April 20 2021 08:23 JST
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
April 14 2021 12:49 JST
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
April 12 2021 12:16 JST
More Press release >>
Latest Press Release
Eisai and National Cancer Center Commence Joint Research and Development Project
May 14, 2021 17:48 JST
TOYOTA GAZOO Racing Leads the WRC onto Gravel
May 14, 2021 17:04 JST
Hitachi ABB Power Grids enables Minnesota Power to deliver more clean and affordable hydropower to the U.S. Upper Midwest region
May 14, 2021 15:24 JST
NEC X and Alchemist Accelerator Announce Partnership to Speed Successful Startup Launches
May 14, 2021 14:02 JST
Mitsubishi Power Achieves #1 Market Share Globally in the First Quarter of 2021 According to McCoy Power Report
May 13, 2021 18:29 JST
Showa Denko Announces 2021 First Quarter Financial Results
May 13, 2021 15:30 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony in Shimonoseki for Large Ferry Built for Meimon Taiyo Ferry
May 13, 2021 15:06 JST
MHI Thermal Systems fully revises a lineup of inverter multi-split air conditioners for buildings in its overseas markets
May 13, 2021 14:06 JST
MHI Thermal Systems Confirms Effectiveness of Air Purification Filtering Technology for Removal and Inactivation of SARS-CoV-2
May 12, 2021 12:17 JST
Collaboration with South Pole to Generate and Sell Carbon Credits from Carbon Removal Technologies
May 12, 2021 12:02 JST
Fujitsu Signs Strategic Collaboration Agreement with AWS to Accelerate Digital Transformation in the Mobility Industry
May 12, 2021 10:51 JST
Mitsubishi Power Receives Turnkey Order for 50MW Woody Biomass-fired Power Generation Facility
May 11, 2021 18:39 JST
Eisai's Statement of Commitment for Carbon Neutrality by 2040
May 11, 2021 10:00 JST
ENEOS and Toyota Come Together to Make Woven City the Most Hydrogen-Based Society
May 10, 2021 15:38 JST
Showa Denko Revises Forecast of Consolidated Performance and to Record Extraordinary Loss
May 10, 2021 11:30 JST
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications
May 07, 2021 11:08 JST
Showa Denko and Infineon Technologies Conclude Supply Contract and Development Agreement
May 06, 2021 17:30 JST
NEC Develops Neuroscience-inspired AI Technology for Time Series Analysis
May 06, 2021 14:13 JST
NEC Contributes to Development of Artificial DNA Aptamer that Binds to the Novel Coronavirus (SARS-CoV-2)
May 06, 2021 11:27 JST
Synopsis 2021: Hot Trends - Join the Summit 1-5 June
May 04, 2021 09:00 JST
More Latest Release >>